Androgenetic Alopecia
May 2002
in “
PubMed
”
New to Vascular Endothelial Growth Factor? There is a guide in the encyclopedia. Read the guide → androgenetic alopecia 5 alpha reductase dihydrotestosterone dermal papilla vascular endothelial growth factor androgen receptor polymorphism insulin-resistant process polycystic ovary auto-immune origin oestrogens 5 alpha reductase inhibitors AGA DHT VEGF androgen receptor insulin resistance PCOS estrogens
Studysummary This review discusses the androgen-dependent and genetic factors of androgenetic alopecia, highlighting differences in its manifestation between men and women, and reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The 2002 review on Androgenetic alopecia (AGA) discussed that AGA is a result of an androgen-dependent process and genetic transmission. In men, AGA is associated with an increase in 5 alpha reductase activity leading to an increase in local production of dihydrotestosterone, which is believed to inhibit cell proliferation in the dermal papilla and a vascular process based on the inhibition in local production of vascular endothelial growth factor (VEGF). This process is genetic and depends on androgen receptor polymorphism. Male AGA is also associated with an insulin-resistant process and a higher risk of polycystic ovary in the lineage. In women, alopecia is usually diffuse and the mechanisms are different and largely unknown. It is suggested that an auto-immune origin could be involved in some cases. Pharmacological doses of oestrogens have a beneficial effect on such alopecia. In practice, 5 alpha reductase inhibitors are ineffective in women. The review concluded that the predominance observed in the frontal and vertex areas in elderly women is likely a result of the two combined disorders, the almost physiological androgen-dependent hair loss combined with diffuse loss.
